FDA and Health Canada joint regulatory submission pilot

15 January 2023
The U.S. Food and Drug Administration (FDA) is partnering with Health Canada to launch the joint eSTAR pilot. Requests for participating in the pilot are now open.
The pilot will test the use of a single regulatory submission to both the FDA and Health Canada.
The submission will need to include the GMDN Term for the product and therefore will be useful for demonstrating how the GMDN supports international harmonisation using an accurate generic name for the device type. Requests for participating in the pilot are now open.
More information is available from the FDA and Health Canada.
Health Canada
US FDA
www.fda.gov/medical-devices/how-study-and-market-your-device/health-canada-and-fda-estar-pilot
Recent Posts
- GMDN FOCUS – March 2025 March 31, 2025
- Global Medical Device Nomenclature (GMDN): A valuable tool for the development of National Essential Diagnostics Lists (NEDLs) March 25, 2025
- GMDN Agency joins Joint Initiative Council to advance global health informatics March 4, 2025
- GMDN FOCUS – February 2025 February 28, 2025
- Shaping Our Future: Insights and Actions from the GMDN Agency’s 2024 Annual Survey February 27, 2025